Codexis Inc. reported fourth‑quarter 2025 revenue of $38.9 million, an 81% year‑over‑year increase, and net income of $9.6 million, translating to earnings per share of $0.11. The earnings beat the consensus estimate of a $0.04 loss, a swing of $0.15 per share that reflects disciplined cost management and a favorable product mix.
Full‑year 2025 revenue reached $70.4 million, up 19% from $58.5 million in 2024, while the company posted a net loss of $44 million versus a $65.3 million loss the previous year. The narrowing loss is largely attributable to a 24% workforce reduction announced in November 2025, a one‑time restructuring charge of $3.4 million, and the $37.8 million capital recognized from a technology transfer agreement with Merck in Q4 2025.
The Merck agreement generated $37.8 million in capital in the fourth quarter and is expected to produce a small amount of revenue in 2026. The transaction validates Codexis’ technology and provides a significant cash infusion that supports ongoing investment in its ECO Synthesis platform.
The workforce reduction, which cut headcount by roughly a quarter, was part of a broader effort to lower operating expenses and improve margin performance. The associated restructuring charge was recorded in Q4, helping to offset the impact of the reduction on profitability.
Management guided 2026 revenue to $72–$76 million, a range that exceeds consensus estimates and signals confidence in continued demand for enzymatic oligonucleotide manufacturing. The guidance also reflects the company’s belief that its ECO Synthesis platform will drive future growth and that its cash runway will support operations through 2027.
Gross margin improved to 64% for the full year and 65% for Q4, up from 56% and 63% in 2024, respectively. The margin expansion is driven by a higher mix of high‑margin services and the exit from lower‑margin product lines, indicating a more efficient cost structure.
Investors reacted positively to the results, citing the strong earnings beat, revenue growth, margin improvement, and optimistic 2026 guidance as evidence of effective execution and a solid strategic trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.